drugset
drugset / Trial / NCT01105598

A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia

NCT01105598 ↗

Phase 1 Completed 53 enrolled Esperion Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This Phase 1, double-blind (sponsor open) study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of ETC-1002 given to subjects with mild dyslipidemia.

Timeline

Start
2010-04-20
Primary completion
2010-10-02
Completion
2010-10-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Bempedoic acid Small molecule 20 mg —

Indications

No indication recorded.